Lexaria Bioscience has initiated a new 2026 animal study to test improved formulations of its DehydraTECH drug delivery platform, focusing on GLP-1 and CBD compositions. The study aims to enhance drug performance, reduce side effects, and establish new intellectual property claims, particularly targeting alternatives to the SNAC formulation used in leading oral GLP-1 drugs. Using Sprague-Dawley rats, the study will measure drug absorption and brain concentrations to explore superior delivery methods. This effort positions Lexaria to capitalize on the growing market for diabetes and weight loss treatments with oral GLP-1 drugs, with dosing expected to start within 60 days and fully funded by existing resources.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
